N Engl J Med 2007 Aug 16
Prophylactic cranial irradiation in extensive small-cell lung cancer.
Abstract
Background
We conducted a randomized trial of prophylactic cranial irradiation in patients with extensive small-cell lung cancer who had had a response to chemotherapy.
Methods
Patients between the ages of 18 and 75 years with extensive small-cell lung cancer were randomly assigned to undergo prophylactic cranial irradiation (irradiation group) or receive no further therapy (control group). The primary end point was the time to symptomatic brain metastases. Computed tomography or magnetic resonance imaging of the brain was performed when any predefined key symptom suggestive of brain metastases was present.
Results
The two groups (each with 143 patients) were well balanced regarding baseline characteristics. Patients in the irradiation group had a lower risk of symptomatic brain metastases (hazard ratio, 0.27; 95% confidence interval [CI], 0.16 to 0.44; P<0.001). The cumulative risk of brain metastases within 1 year was 14.6% in the irradiation group (95% CI, 8.3 to 20.9) and 40.4% in the control group (95% CI, 32.1 to 48.6). Irradiation was associated with an increase in median disease-free survival from 12.0 weeks to 14.7 weeks and in median overall survival from 5.4 months to 6.7 months after randomization. The 1-year survival rate was 27.1% (95% CI, 19.4 to 35.5) in the irradiation group and 13.3% (95% CI, 8.1 to 19.9) in the control group. Irradiation had side effects but did not have a clinically significant effect on global health status.
Conclusions
Prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases and prolongs disease-free and overall survival. (ClinicalTrials.gov number, NCT00016211 [ClinicalTrials.gov].).
Related Questions
Does omission of PCI influence your decision whether to offer consolidative thoracic radiation in ES-SCLC after chemo + immunotherapy?
This is one of those stories that has evolved over time with our improvements in technology.EORTC 08993 (the Slotman study) demonstrated both an improvement in the rate of symptomatic brain mets at 1 yr from 40% to 15%, and an improvement in 1 yr OS from 13% to 27%. However, a huge caveat here is th...
How would you approach ES-SCLC presenting with small brain metastases that resolve after chemotherapy?
ES-SCLC may respond to chemotherapy, but save for a select few, it’s a palliative disease with, median survival of about a year for responders. Presenting with microscopic brain disease that responds to chemo does not change that. The Slotman report indicating survival advantage has been questioned ...
How do you decide whether to offer PCI in patients with ES-SCLC who cannot get brain MRIs?
The Slotman study that showed a benefit for PCI did not have CNS staging (CT or MRI) done routinely for asymptomatic patients, so I don’t think of it as PCI. Since 30% or so patients with SCLC have brain metastases, this version of “PCI” is just treating brain mets. That’s probably what produced the...
Do you recommend prophylactic cranial irradiation for ES-SCLC patients now that immunotherapy is included in the treatment schema?
I do not pursue PCI for most patients with extensive stage SCLC. We know the EORTC phase III study led by Ben Slotman (NEJM 2007) showed a decrease in the cumulative risk of brain metastases that translated into a survival benefit. One of the flaws of the study was the lack of baseline and regular M...
Would you consider PCI for a patient with neuroendocrine carcinoma of the esophagus?
No. The role of PCI is currently being reconsidered even for lung small cell lung cancer - where PCI has been established after Auperin meta-analysis in Limited Stage and EORTC randomized trial in Extensive Stage. The problem with older studies - both the older studies from 1980s that were included ...
Is it reasonable to offer observation with MRI rather than immediate PCI for patients with limited stage SCLC?
This is an important question with implications for both overall survival (OS) and quality of life (QOL) where level-1 evidence is currently lacking. It is also the subject of an ongoing phase 3 trial (SWOG S1827/Maverick) that randomizes patients with limited-stage (LS) and extensive-stage (ES) SCL...
When is it too far out from CRT to the chest to be considered for PCI for limited-stage SCLC?
How about this answer that was not listed - "don't give it!" The evidence we hang our hat for PCI in SCLC is not just weak, it is also outdated. With the medical technology available they had at the time, it made logical sense that staging would miss brain metastases. ~50% of the studies in the meta...
When is it appropriate to recommend SBRT directed to sites of oligometastasis (ex, single adrenal met) for a patient with extensive stage small cell s/p chemo and PCI?
May I play devil's advocate for one moment? I don't wholly disagree with @Dr. First Last btw, fwiw.1) Some people with SCLC can be cured. It appears that the application of a local therapy in limited stage SCLC increases the chance for long-term DFS (aka "a cure"). Five-year survival was doubled fro...
Do you ever withhold PCI for elderly patients with limited stage SCLC?
In my opinion, the findings by Takahashi et al, Lancet 2017 regarding the lack of survival benefit of PCI as compared to MRI observation in patients with extensive SCLC has re-opened the question of the survival benefit of PCI in limited SCLC in the modern imaging era. Hopefully, a phase III study o...
Should consolidative RT for extensive stage SCLC be given before, after, or concurrently with PCI?
Great question, and to my knowledge there's not a lot of data to guide this so I dont think there's a wrong answer.Before the CREST trial, my practice was to do PCI first, because I felt that the evidence for an OS benefit was much stronger, and it was therefore more improtant to get this completed ...
How do you incorporate PCI into your management of patients with extensive stage SCLC?
The role of prophylactic cranial irradiation (PCI) in the modern era of brain MRI surveillance has been called into question and is the topic of the ongoing phase 3 SWOG S1827/Maverick trial of MRI surveillance +/- PCI (or hippocampal avoidance [HA]-PCI) for LS and ES-SCLC, where I serve as the prin...
Is it acceptable to treat newly diagnosed small cell lung cancer with limited brain metastasis with upfront SRS?
First, to be clear, there's not good evidence regarding the role of radiosurgery in small cell patients who have not had WBRT or PCI. In patients without brain metastases, there's a clearly defined and clinically significant survival benefit, which seems to result from both control of existing metas...